Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey.
about
Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi PanelAssessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across GermanyThe Role of Biosimilars in Inflammatory Bowel Disease.CT-P13 in the treatment of rheumatoid arthritis.Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer.Long-Term Clinical Outcomes After Switching from Remicade(®) to Biosimilar CT-P13 in Inflammatory Bowel Disease.Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey.Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.Safety considerations of biosimilarsPolicy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching.Mesenchymal stromal cells modulate gut inflammation in experimental colitis.A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.Biosimilars in paediatric inflammatory bowel diseasePreparing for the incoming wave of biosimilars in oncology
P2860
Q33740641-6CC27D63-8986-4012-931D-EA49F6DAB5D2Q36347183-6FA34625-6FD2-4021-B80F-90B890B87541Q37540190-BB681ADF-2B8E-41B0-A0F2-CEDDAAA4B63EQ38676104-CDDC3491-BBB6-4B00-AB32-0D38F5C6E119Q38686396-533FB8FD-0C5A-46F8-95F0-B35B4F0C4EB0Q38699157-A417B8CD-58C2-4B61-89C9-8A8DCB041B76Q38715043-3E062397-2237-4CDC-A4EB-63A47FB51C17Q38824505-0B4DBDEE-316E-4B94-815B-5D5163349E32Q39016810-737AF774-B798-4B48-B4CC-38C9C5FE88F2Q42353230-12E73703-6869-4B62-8E2E-C7235DE87D1EQ48092457-3671AE5A-BFE6-4021-97F7-11F6CE5542C6Q48140849-6BE9DD75-0FA0-40B7-B2C8-CD040497177FQ50073683-E7B341CE-DBF0-4DC7-98DE-27D10903CBF4Q51280643-DCFD7C23-EF40-4397-B264-B94F1FC7314DQ58707780-FFE66229-2A8A-4697-9DCC-A94349E393DAQ58762727-1EE8FFD1-2DA3-4028-B07F-776F9D0BB8A4
P2860
Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Changes in Biosimilar Knowledg ...... O] Members: An Updated Survey.
@en
Changes in Biosimilar Knowledg ...... O] Members: An Updated Survey.
@nl
type
label
Changes in Biosimilar Knowledg ...... O] Members: An Updated Survey.
@en
Changes in Biosimilar Knowledg ...... O] Members: An Updated Survey.
@nl
prefLabel
Changes in Biosimilar Knowledg ...... O] Members: An Updated Survey.
@en
Changes in Biosimilar Knowledg ...... O] Members: An Updated Survey.
@nl
P356
P1476
Changes in Biosimilar Knowledg ...... CO] Members: An Updated Survey
@en
P2093
Pierre Michetti
Silvio Danese
P304
P356
10.1093/ECCO-JCC/JJW090
P577
2016-04-25T00:00:00Z